Abstract
The aim of the study was to investigate the serum albumin conformation in patients with melancholic depression. There were investigated 22 patients with melancholic depression and 54 healthy volunteers. Patients with melancholic depression were investigated in dynamics of the antidepressive therapy (venlafaxine, 75–150 mg/daily): at admission, on 15th and 30th days. Subnanosecond laser time resolved fluorescence spectroscopy with K-35 fluorescent probe (dimethylaminonaphthalic acid N-carboxyphenylimide, CAPIDAN) was used for the investigation of albumin conformation There were revealed in controls 3 binding site for the probe on albumin molecule with decay times of 1, 3 and 9 nanoseconds (amplitudes A3, A2, and A1, respectively). The mean amplitudes A3, A2, and A1 in the serum albumin of patients with melancholic depression were significantly higher than in controls (p = 0.025). After antidepressive therapy with venlafaxine there was revealed that all three amplitudes significantly decreased and were equal to the amplitudes of controls. We can hypothesize that investigated parameters can serve as potential biomarkers for the evaluation of the efficacy of the psychopharmacotherapy.
Similar content being viewed by others
REFERENCES
Kreisel, T., Frank, M.G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M.V., S.F. Maier, S.F., and Yirmiya, R., Mol. Psychiatry, 2013, vol. 10, pp. 155–163.
Kessler, R. C., and Ustun, T.B. (Eds.): The WHO World Mental Health Surveys: Global perspectives on the epidemiology of mental disorders. New York: Cambridge University Press 2008.
Krasnov, V.N., Korsakov Zh. Nevrol. Psychiat., 2012, vol. 112, pp. 3–11.
Uzbekov, M.G., Biochemistry (Moscow), vol. 86, no. 6, pp. 773–783
Grieve, S.M., Korgaonkar, M.S., Etkin, A., Harris, A., Koslow, S.H., Wisniewski, S., Schatzberg, A.F., Nemeroff, C.B., Gordon, E., and Williams, L.M., Trials, 2013, vol. 14, pp. 224– 232.
Lopukhin, Yu.M., Dobretsov, G.E., and Gryzunov, Yu.A., Bull. Exper. Biol. Med., 2000, vol. 130, pp. 615–619.
Prusiner, S.B., Proc. Natl. Acad. Sci., 1998, vol. 95, pp. 13363–13383.
Uzbekov, M.G., Misionzhnik, E.Yu., Gurovich, I.Y., and Shmukler, A.B., Acta Neuropsychiatrica, 2013, vol. 25, pp. 268–274.
Dobretsov, G., Syrejshchikova, T., Smolina, N., and Uzbekov, M., Human Serum Albumin, Ed. Stokes T. New York: Nova Science Publishers, 2015, pp. 129–171.
Uzbekov, M., Dobretsov, G., Syrejshchikova, T., and Smolina, N., Contemporary medical technologies, 2011, vol. 6, pp. 68–71.
Hamilton, M. Handbook of Anxiety Disorders, Eds. Last C., Hersen M., Oxford: Pergamon Press, 1988, pp. 143–155.
Syrjeshchikova, N.I., Smolina, N.V., Uzbekov, M.G., Dobretsov, G.E., Kalinina, V.V., Krjukov, V.V., Antipova, O.S., Emeljanova, I.N., and Krasnov, V.N., Korsakov Zh. Nevrol. Psychiat., 2015, vol. 115, pp. 47–50.
Gryzunov, Yu.A., and Dobretsov, G.E., Protein Conformation: New Research, Ed. Roswell L.B., New York: Nova Publ., 2008, pp. 125–159.
Syrejshchikova, T.I., Gryzunov, Yu.A., Smolina, N.V., Komar, A.A., Uzbekov, M.G., Misionzhnik, E.Yu., and Maximova, N.M., Laser Physics, 2010, vol. 20, pp. 1074–1078.
Dobretsov, G.E., Gryzunov, Yu.A., T. I. Syrejshchikova, T.I., and Smolina, N.V., J. Fluorescence, 1998, vol. 8, pp. 27–35.
Dobretsov, G.E., Polyak, B., Smolina, N., Babushkina, T., Syrejshchikova, T., Klimova, T., Sverbil, V., Peregudov, A., Gryzunov, Yu., and Sarkisov, O., J. Photochem. Photobiol. A Chem., 2013, vol. 251, pp. 134–140.
Uzbekov, M., Syrejshchikova, T., Smolina, N., Maximova, N., Shikhov, S., and Brilliantova, V., Biomed. J. Sci. Tech. Res., 2019, vol. 21, pp. 16103–16105.
Uzbekov, M., Brilliantova, V., Shikhov, S., Syrejshchikova, T., Dobretsov, G., and Maximova, N., European Neuropsychopharmacology, 2019, vol. 29, pp. S96–97.
Funding
No external funding was received.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests. The authors declare that they have no conflicts of interest.
Ethical approval. Investigation was performed in accordance of the Helsinki Declaration for experiments involving humans and the permission of the local ethical committee of Moscow Research Institute of Psychiatry (N 16, 13.03.2017).
Informed consent. Informed consent for participation in the study was obtained from all subjects.
Additional information
Corresponding author; address: ul. Poteshnaya 3, korp. 10, Moscow, 107076 Russia; phone: +7(495) 963-76-26; e-mail: uzbekovmg@gmail.com
Rights and permissions
About this article
Cite this article
Uzbekov, M.G., Smolina, N.V., Syrejshchikova, T.I. et al. Investigation of Serum Albumin Conformational Changes in Melancholic Depression under Pharmacotherapy Using Subnanosecond Fluorescent Spectroscopy. Neurochem. J. 16, 480–484 (2022). https://doi.org/10.1134/S1819712422040213
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712422040213